Strategies for the Chemoprevention of Prostate Cancer

Lieberman, Ronald; Kagan, Jacob; House, Margaret G.; Kelaghan, Joseph; Kansal, David J.; Parnes, Howard L.

doi:10.1007/978-1-59259-776-5_5

Cited by 3 publications

References 172 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Can prostate cancer be prevented?

Klein

2005

Nat Rev Urol

View full text Add to dashboard Cite

The goal of primary chemoprevention is to decrease the incidence of a given cancer, simultaneously reducing both treatment-related adverse events and mortality. Prostate cancer is an attractive and appropriate target for primary prevention because of its incidence, prevalence, and disease-related mortality; its long latency and molecular pathogenesis; and epidemiologic data indicating that modifiable environmental factors may decrease risk. The Prostate Cancer Prevention Trial (PCPT) demonstrated that finasteride can prevent prostate cancer, albeit with an apparently increased risk of high-grade disease. A substantial amount of epidemiologic, molecular, and clinical evidence suggests that both selenium and vitamin E might also prevent prostate cancer, and this combination is being tested in the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Ultimately, the adoption of a preventive strategy hinges on its potential benefits weighed against the potential risks of the specific agents used.

show abstract

Can prostate cancer be prevented?

Klein

2005

Nat Rev Urol

View full text Add to dashboard Cite

show abstract

Chemoprevention of Prostate Cancer

Klein

2006

Annu. Rev. Med.

View full text Add to dashboard Cite

Prostate cancer is an attractive target for chemoprevention because of its ubiquity, treatment-related morbidity, long latency between premalignant lesions and clinically evident cancer, and defined molecular pathogenesis. The Prostate Cancer Prevention Trial has provided the first firm evidence that this cancer can be prevented by a relatively nontoxic oral agent. Additional agents, many of which are antioxidants with antiandrogenic effects, are being tested (or soon will be) in large clinical trials. The current body of evidence is insufficient to make a routine recommendation of any dietary or nutritional supplement for the prevention of prostate cancer.

show abstract